Dyslipidemia Patients With Hypertension
Conditions
Brief summary
Clinical Trial to Evaluate the Efficacy and Safety of CKD-386
Interventions
DRUGD013, D326, D337
Experimental: Group 1 Patients assigned to this group are treated with D013, D326, D337
DRUGplacebo of D013, D326, D337
Placebo Comparator: Group 1 Patients assigned to this group are treated with D326, D337, placebo of D013
DRUGD013, placebo of D326, placebo of D337
Placebo Comparator: Group 2 Patients assigned to this group are treated with D013, placebo of D326, placebo of D337
Sponsors
Chong Kun Dang Pharmaceutical
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Investigator)
Eligibility
Sex/Gender
ALL
Age
19 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Subjects are diagnosed with Dyslipidemia Patients with Hypertension or are being administered anti-hypertension and anti-hypertension drugs after diagnosis. 2. Subjects who agreed to participate in this clinical trial voluntarily.
Exclusion criteria
1. Subjects who were satisfied specific blood pressure levels that measured at screening period. 2. Subjects who were satisfied specific lipid levels that measured at screening period. 3. Subjects who cannot participate in a clinical trial based on the PI's judgment.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Change rate from baseline in LDL-C | 8 weeks after drug administrations | Compare experimental group 1 with comparator group 1 |
| Change from baseline in MSSBP | 8 weeks after drug administrations | Compare experimental group 1 with comparator group 2 |
Countries
South Korea
Outcome results
None listed